Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

Change of CD20 Expression in Diffuse Large B-Cell Lymphoma Treated with Rituximab, an Anti-CD20 Monoclonal Antibody: A Study of the Osaka Lymphoma Study Group

Change of CD20 expression was examined in cases of diffuse large B-cell lymphoma (DLBCL). CD20 expression after treatment with anti-CD20 antibody (rituximab, Rx) for DLBCL was examined in 23 cases who received serial biopsy by immunohistochemistry (IHC) and flow cytometry (FCM). CD20– by IHC and/or...

Full description

Bibliographic Details
Main Authors: Naoki Wada, Masaharu Kohara, Hiroyasu Ogawa, Haruo Sugiyama, Shirou Fukuhara, Yoichi Tatsumi, Akihisa Kanamaru, Masayuki Hino, Yuzuru Kanakura, Eiichi Morii, Katsuyuki Aozasa
Format: Article
Language:English
Published: Karger Publishers 2009-10-01
Series:Case Reports in Oncology
Subjects:
CD20
Relapse
Diffuse large B-cell lymphoma
Rituximab
Clonality
Online Access:http://www.karger.com/Article/FullText/249152

Internet

http://www.karger.com/Article/FullText/249152

Similar Items